{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:11:55Z","timestamp":1648905115070},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11657-021-01007-3","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T06:49:47Z","timestamp":1633416587000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Teriparatide in individuals with a prior history of radiation therapy\u2014a case series"],"prefix":"10.1007","volume":"16","author":[{"given":"Yee-Ming Melody","family":"Cheung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole-Petter Riksfjord","family":"Hamnvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"1007_CR1","unstructured":"FDA (2021) Full prescribing information for FORTEO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021318s053lbl.pdf. Accessed 17 Aug 2021\u00a0"},{"key":"1007_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00198-020-05718-0","volume":"32","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Harris D, Reynolds M et al (2021) Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int 32:645\u2013651","journal-title":"Osteoporos Int"},{"key":"1007_CR3","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/pds.5103","volume":"29","author":"A Gilsenan","year":"2020","unstructured":"Gilsenan A, Midkiff K, Harris D et al (2020) Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf 29:1616\u20131626","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1007_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/pds.4008","volume":"25","author":"KD Midkiff","year":"2016","unstructured":"Midkiff KD, Andrews EB, Gilsenan AW et al (2016) The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication. Pharmacoepidemiol Drug Saf 25:960\u2013968","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1007_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/1097-0142(19831015)52:8<1489::AID-CNCR2820520826>3.0.CO;2-X","volume":"52","author":"AG Huvos","year":"1983","unstructured":"Huvos AG, Butler A, Bretsky SS (1983) Osteogenic sarcoma associated with Paget\u2019s disease of bone. A clinicopathologic study of 65 patients. Cancer 52:1489\u20131495","journal-title":"Cancer"},{"key":"1007_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety. Toxicol Pathol 30:312\u2013321","journal-title":"Toxicol Pathol"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43\u201366","journal-title":"CA Cancer J Clin"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","volume":"16","author":"DB Burr","year":"2001","unstructured":"Burr DB, Hirano T, Turner CH et al (2001) Intermittently administered human parathyroid hormone(1\u201334) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157\u2013165","journal-title":"J Bone Miner Res"},{"key":"1007_CR9","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","volume":"30","author":"AJ Swerdlow","year":"2012","unstructured":"Swerdlow AJ, Cooke R, Bates A et al (2012) Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 30:2745\u20132752","journal-title":"J Clin Oncol"},{"key":"1007_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med 373:2499\u20132511","journal-title":"N Engl J Med"},{"key":"1007_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","volume":"99","author":"IM Krul","year":"2017","unstructured":"Krul IM, Opstal-van Winden AWJ, Aleman BMP et al (2017) Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure. Int J Radiat Oncol Biol Phys 99:843\u2013853","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1007_CR12","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/1097-0142(197906)43:6<2178::AID-CNCR2820430603>3.0.CO;2-9","volume":"43","author":"WP Thorpe","year":"1979","unstructured":"Thorpe WP, Reilly JJ, Rosenberg SA (1979) Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43:2178","journal-title":"Cancer"},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G et al (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"1007_CR14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"1007_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CIA.S4080","volume":"4","author":"P Rackoff","year":"2009","unstructured":"Rackoff P (2009) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging 4:207\u2013214","journal-title":"Clin Interv Aging"},{"key":"1007_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1007_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1007_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1007_CR19","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"1007_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","volume":"86","author":"J Jolette","year":"2017","unstructured":"Jolette J, Attalla B, Varela A et al (2017) Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334). Regul Toxicol Pharmacol Regul Toxicol Pharmacol 86:356\u2013365","journal-title":"Regul Toxicol Pharmacol Regul Toxicol Pharmacol"},{"key":"1007_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Matsumoto T (2021) Sclerostin: from bench to bedside. J Bone Miner Metab 39:332\u2013340","journal-title":"J Bone Miner Metab"},{"key":"1007_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","volume":"16","author":"K Banfill","year":"2021","unstructured":"Banfill K, Giuliani M, Aznar M et al (2021) Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. Thorac Oncol 16:216\u2013227","journal-title":"Thorac Oncol"},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1667\/RR0527.1","volume":"167","author":"H Suit","year":"2007","unstructured":"Suit H, Goldberg S, Niemierko A et al (2007) Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res 167:12\u201342","journal-title":"Radiat Res"},{"key":"1007_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D et al (2021) Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res 36:244\u2013251","journal-title":"J Bone Miner Res"},{"key":"1007_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","volume":"21","author":"V Subbiah","year":"2010","unstructured":"Subbiah V, Madsen VS, Raymond AK et al (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041\u20131045","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-01007-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-021-01007-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-01007-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T15:05:05Z","timestamp":1642086305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-021-01007-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s11657-021-01007-3","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"149"}}